Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 19Recurrence 1Plasmablastic Lymphoma 1

Interventions

Etoposide 4Vincristine 3Rituximab 3Prednisone 3Doxorubicin 3Cyclophosphamide 3prednylidene 2deltacortene 2Cytarabine 2varlilumab 1merphos 1ixazomib 1carmustine, poliferprosan 20 drug combination 1belantamab mafodotin 1Vorinostat 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Methotrexate 1Melphalan 1Immunoglobulin G 1Hydrocortisone 1Disulfides 1Carmustine 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Plasmablastic Lymphoma × belantamab mafodotin × Clear all
NCT04676360 2026-03-13

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

Massachusetts General Hospital

Phase 2 Terminated
10 enrolled 11 charts
Lymphoid

Plasmablastic Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡